<GlossaryTerm id="CDR0000795540"><TermName>lorlatinib</TermName><TermPronunciation>(lor-LA-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat adults with non-small cell lung cancer that has spread to other parts of the body and is ALK positive. It is also being studied in the treatment of other types of cancer. Lorlatinib blocks certain proteins made by the <GeneName>ALK</GeneName> gene. Blocking these proteins may stop the growth and spread of cancer cells. Lorlatinib is a type of tyrosine kinase inhibitor. Also called Lorbrena.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000796219" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lorlatinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000796218" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lorlatinib&quot;" language="es" id="_4"/><SpanishTermName>lorlatinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para el tratamiento de adultos con cáncer de pulmón de células no pequeñas positivo para ALK que se diseminó a otras partes del cuerpo. También está en estudio para el tratamiento de otros tipos de cáncer. El lorlatinib bloquea ciertas proteínas que se originan del gen <GeneName>ALK</GeneName>, lo que quizás impida la multiplicación y diseminación de las células cancerosas. El lorlatinib es un tipo de inhibidor de tirosina–cinasas. También se llama Lorbrena.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2018-11-06</DateFirstPublished><DateLastModified>2021-03-18</DateLastModified><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000795538" url="/about-cancer/treatment/drugs/lorlatinib">Lorlatinib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
